Metastatic Hormone Refractory Prostate Cancer Recruiting Phase 1 Trials for Apalutamide (DB11901)

Also known as: Metastatic hormone refractory Prostate cancer / Metastatic Prostate cancer / Prostate cancer metastatic / Metastatic Prostate Carcinoma / Carcinoma of the prostate metastatic / Prostatic cancer metastatic

IndicationStatusPhase
DBCOND0036371 (Metastatic Hormone Refractory Prostate Cancer)Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02913196Phase I Trial of Apalutamide Plus Abiraterone Acetate, Docetaxel, and Prednisone in Patients With mCRPCTreatment